These results highlighted that immune checkpoint inhibitors combined with anti‐angiogenic drugs and chemotherapy can improve survival outcomes for patients with advanced NSCLC who have failed EGFR‐TKI treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.